RNA-seq analysis of co-treatment with gemcitabine and N-Methyl-(5-pyrid-3- ylthien-2-yl)methylamine in PANC-1 cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterised by rapid metastasis and marked chemoresistance. The absence of early symptoms and reliable diagnostic markers makes timely detection clinically challenging, and progress in developing new therapeutics has been limited. This project aims to establish a new class of non-toxic drug sensitiser, N-methyl-(5-pyrid-3-ylthien-2-yl)methylamine (B10), termed a binary drug (BD), identified through screening of a Maybridge chemical fragment library, which enhances gemcitabine-induced killing of pancreatic cancer cells when co-administered by targeting drug-resistance-related efflux transporters and key oncogenic pathways.